


PRODUCT INFORMATION



Menaquinone 4

Item No. 18423

CAS Registry No.: 863-61-6
Formal Name: 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-1,4-naphthalenedione
Synonyms: MK-4, Vitamin K₂₍₂₀₎
MF: C₃₁H₄₀O₂
FW: 444.7
Purity: ≥98%
UV/Vis.: λ_{max}: 248, 269, 329 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Menaquinone 4 is supplied as a crystalline solid. A stock solution may be made by dissolving the menaquinone 4 in the solvent of choice, which should be purged with an inert gas. Menaquinone 4 is soluble in the organic solvent chloroform. The solubility of menaquinone 4 in this solvent is approximately 100 mg/ml.

Description

Menaquinone 4 (MK-4) is the predominant homolog of vitamin K₂ and is composed of a naphthoquinone base with four isoprenoid units in the side chain.¹ It is formed primarily *via* conversion of vitamin K₁ (Item No. 21051) *in vivo* and accumulates in various tissues, including the brain.^{2,3} MK-4 halts the cell cycle at the G₁ phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner.⁴ It also inhibits IκB kinase (IKK) activity, IκBα phosphorylation, and the transcriptional activity of NF-κB. Vitamin K₂ may have a role in bone metabolism.¹

References

1. Plaza, S.M. and Lamson, D.W. Vitamin K2 in bone metabolism and osteoporosis. *Altern. Med. Rev.* **10(1)**, 24-35 (2005).
2. Shearer, M.J. and Newman, P. Metabolism and cell biology of vitamin K. *Thromb. Haemost.* **100(4)**, 530-547 (2008).
3. Okano, T., Shimomura, Y., Yamane, M., *et al.* Conversion of phylloquinone (vitamin K₁) into menaquinone-4 (vitamin K₂) in mice: Two possible routes for menaquinone-4 accumulation in cerebra of mice. *J. Biol. Chem.* **283(17)**, 11270-11279 (2008).
4. Ozaki, I., Zhang, H., Mizuta, T., *et al.* Menatetrenone, a vitamin K₂ analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D₁ expression through inhibition of nuclear factor κB activation. *Clin. Cancer Res.* **13(7)**, 2236-2245 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM